{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:59Z","timestamp":1791298499659,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperkalemia is common in chronic kidney disease (CKD) and chronic heart failure (CHF), often leading to treatment dilemmas regarding renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors. Although potassium binders and dietary restrictions are central to chronic management, their quality-of-life (QOL) impact remains insufficiently described. This study aimed to characterize real-world treatment patterns and evaluate treatment impact on QOL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed baseline data from a prospective cohort in Japanese nephrology and cardiology outpatient clinics. Participants were adults with CKD (\u2265\u2009stage G3) or CHF (New York Heart Association class II-IV) who initiated potassium binders within 6\u00a0months. Clinical data, serum potassium values, and patient-reported outcomes (generic QOL, disease\/treatment-specific QOL, and adherence measures) were obtained at enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 347 patients, the median age was 75\u00a0years, and 74% were male; 93% had CKD. At enrollment, 59% were prescribed a RAAS inhibitor. Dietary therapy was implemented in 29%. Physical scores of generic QOL were lower than population norms, whereas mental scores were comparable. Treatment-specific QOL scores suggested that potassium binders may have had a relatively small impact on QOL compared with dietary therapy. Adherence to potassium binders was high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Concurrent use of RAAS inhibitors and potassium binders was common, consistent with a role for binders in supporting RAAS inhibitor continuation. Potassium binders showed little perceived impact, indicating that pharmacologic potassium control may be acceptable to patients managing multiple lifestyle limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study registration.<\/jats:title>\n                    <jats:p>The study was registered with ClinicalTrials.gov (NCT05297409).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02951-5","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:39:06Z","timestamp":1791297546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life in hyperkalemia: baseline analysis of a cohort study of management of hyperkalemia in patients with chronic kidney disease or heart failure in Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-0818","authenticated-orcid":false,"given":"Ken-ei","family":"Sada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-4370","authenticated-orcid":false,"given":"Hajime","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-5918","authenticated-orcid":false,"given":"Takafumi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1104-2612","authenticated-orcid":false,"given":"Yosuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-5276","authenticated-orcid":false,"given":"Jui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3097-277X","authenticated-orcid":false,"given":"Yoshihiro","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadateru","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4496-9812","authenticated-orcid":false,"given":"Ryotaro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5564-2818","authenticated-orcid":false,"given":"Masayoshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-1495","authenticated-orcid":false,"given":"Shunichi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2951_CR1","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","volume":"34","author":"RW Hunter","year":"2019","unstructured":"Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34:iii2-11.","journal-title":"Nephrol Dial Transplant"},{"key":"2951_CR2","doi-asserted-by":"publisher","first-page":"iii36","DOI":"10.1093\/ndt\/gfz225","volume":"34","author":"AY-M Wang","year":"2019","unstructured":"Wang AY-M. Optimally managing hyperkalemia in patients with cardiorenal syndrome. Nephrol Dial Transplant. 2019;34:iii36-44.","journal-title":"Nephrol Dial Transplant"},{"key":"2951_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029565","volume":"12","author":"S Tsukamoto","year":"2023","unstructured":"Tsukamoto S, Uehara T, Azushima K, Wakui H, Tamura K. Updates for cardio-kidney protective effects by angiotensin receptor-neprilysin inhibitor: requirement for additional evidence of kidney protection. J Am Heart Assoc. 2023;12:e029565.","journal-title":"J Am Heart Assoc"},{"key":"2951_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jash.2017.09.011","volume":"11","author":"CP Kovesdy","year":"2017","unstructured":"Kovesdy CP, Appel LJ, Grams ME, Gutekunst L, McCullough PA, Palmer BF, et al. Potassium homeostasis in health and disease: a scientific workshop cosponsored by the national kidney foundation and the American society of hypertension. J Am Soc Hypertens. 2017;11:783\u2013800.","journal-title":"J Am Soc Hypertens"},{"key":"2951_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","volume":"4","author":"N Kashihara","year":"2019","unstructured":"Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Rep. 2019;4:1248\u201360.","journal-title":"Kidney Int Rep"},{"key":"2951_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ncpneph0510","volume":"3","author":"S Fukuhara","year":"2007","unstructured":"Fukuhara S, Yamazaki S, Hayashino Y, Green J. Measuring health-related quality of life in patients with end-stage renal disease: why and how. Nat Clin Pract Nephrol. 2007;3:352\u20133.","journal-title":"Nat Clin Pract Nephrol"},{"key":"2951_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074090","volume":"13","author":"Y Shibagaki","year":"2023","unstructured":"Shibagaki Y, Yamazaki H, Wakita T, Ware JE, Wang J, Onishi Y, et al. Impact of treatment of hyperkalaemia on quality of life: design of a prospective observational cohort study of long-term management of hyperkalaemia in patients with chronic kidney disease or chronic heart failure in Japan. BMJ Open. 2023;13:e074090.","journal-title":"BMJ Open"},{"key":"2951_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MLR.0000000000002122","volume":"63","author":"JE Ware Jr","year":"2025","unstructured":"Ware JE Jr. Improved Items for estimating SF-36 profile and summary component scores: construction and validation of an 8-Item QOL general (QGEN) survey. Med Care. 2025;63:300\u201310.","journal-title":"Med Care"},{"key":"2951_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-016-0483-x","volume":"14","author":"JE Ware Jr","year":"2016","unstructured":"Ware JE Jr, Gandek B, Guyer R, Deng N. Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL disease impact scale (QDIS\u00ae). Health Qual Life Outcomes. 2016;14:84.","journal-title":"Health Qual Life Outcomes"},{"key":"2951_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05963-5","volume":"15","author":"S Fukuhara","year":"2025","unstructured":"Fukuhara S, Green J, Wakita T, Yamamoto Y, Yamazaki H, Ware JE Jr. The QDIS-7: using one scale to measure the disease-specific quality-of-life impact of different medical conditions. Sci Rep. 2025;15:21756.","journal-title":"Sci Rep"},{"key":"2951_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.37737\/ace.23003","volume":"5","author":"S Fukuhara","year":"2023","unstructured":"Fukuhara S, Yamazaki H, Wakita T, Ware JE Jr, Wang J, Onishi Y, et al. Validation of a new instrument for measuring disease-specific quality of life: a pilot study among patients with chronic kidney disease and hyperkalemia. Ann Clin Epidemiol. 2023;5:13\u20139.","journal-title":"Ann Clin Epidemiol"},{"key":"2951_CR12","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: L. Erlbaum Associates; 1988.","edition":"2"},{"key":"2951_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/ehf2.15171","volume":"12","author":"CV Pollack Jr","year":"2025","unstructured":"Pollack CV Jr, Arroyo D, Kanda E, L\u00e1zaro IJS, Les\u00e9n E, Franz\u00e9n S, et al. Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode. ESC Heart Fail. 2025;12:1776\u201385.","journal-title":"ESC Heart Fail"},{"key":"2951_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1253\/circj.CJ-24-0844","volume":"89","author":"T Kitai","year":"2025","unstructured":"Kitai T, Maruyama S, Kuwahara K, Tamura K, Kinugawa K, Kashihara N. Establishing cross-specialty expert consensus on the optimal management of hyperkalemia in patients with heart failure and chronic kidney disease. Circ J. 2025;89:470\u20138.","journal-title":"Circ J"},{"key":"2951_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.sapharm.2021.02.010","volume":"17","author":"A Al-Mansouri","year":"2021","unstructured":"Al-Mansouri A, Al-Ali FS, Hamad AI, Mohamed Ibrahim MI, Kheir N, Ibrahim RA, et al. Assessment of treatment burden and its impact on quality of life in dialysis-dependent and pre-dialysis chronic kidney disease patients. Res Social Adm Pharm. 2021;17:1937\u201344.","journal-title":"Res Social Adm Pharm"},{"key":"2951_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.hrtlng.2021.02.003","volume":"50","author":"OK Nordfonn","year":"2021","unstructured":"Nordfonn OK, Morken IM, Bru LE, Larsen AI, Huseb\u00f8 AML. Burden of treatment in patients with chronic heart failure - a cross-sectional study. Heart Lung. 2021;50:369\u201374.","journal-title":"Heart Lung"},{"key":"2951_CR17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.amjmed.2020.06.018","volume":"133","author":"M Burgermaster","year":"2020","unstructured":"Burgermaster M, Rudel R, Seres D. Dietary sodium restriction for heart failure: a systematic review of intervention outcomes and behavioral determinants. Am J Med. 2020;133:1391\u2013402.","journal-title":"Am J Med"},{"key":"2951_CR18","volume":"4","author":"SC Palmer","year":"2017","unstructured":"Palmer SC, Maggo JK, Campbell KL, Craig JC, Johnson DW, Sutanto B, et al. Dietary interventions for adults with chronic kidney disease. Cochrane Database Syst Rev. 2017;4:CD011998.","journal-title":"Cochrane Database Syst Rev"},{"issue":"105","key":"2951_CR19","first-page":"S117","volume":"2024","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;2024(105):S117\u2013314.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02951-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:39:07Z","timestamp":1791297547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02951-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":19,"alternative-id":["2951"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02951-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Employment: Tadateru Hamada, Ryotaro Ide, and Masayoshi Takeda (AstraZeneca K.K.), Consultancies: Yosuke Yamamoto (Nippon Shinyaku Co.), Honoraria: Ken-ei Sada (AstraZeneca K.K.), Yugo Shibagaki (AstraZeneca K.K., Otsuka Pharma Co., and Kyowa Kirin Co.), Hajime Yamazaki (Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Kowa Company Limited, AstraZeneca K.K., and Takeda Pharmaceutical Company Limited.), Yosuke Yamamoto (Sun Pharma, Asahi Kasei Pharma, Toray Industries, Inc., and Ono Pharmaceutical Co., Ltd.). Unrelated to the submitted work, consultation fees for Hajime Yamazaki and Shunichi Fukuhara were paid to Kyoto University under contracts with Takeda Pharmaceutical Co., Ltd. and Magmitt Pharmaceutical Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (as listed below) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Azumino Red Cross Hospital Ethics Committee, R04-A-02; Ethics Committee of Kasugai Municipal Hospital, 22\u20137; Komatsu Ishikawa Central Hospital Ethics Committee, R4-6; Non-Profit Organization MINS Research Ethics Committee, MINS-REC-220204; Hiroshima City Hiroshima Citizens Hospital Ethics Review Committee, 2022\u201325; Saga Memorial Hospital Ethics Committee, 9\/3\/2022; Ethics Committee on Epidemiological and its related Studies, Sakuragaoka Campus, Kagoshima University, 220154; Clinical Ethics Committee of New Tokyo Hospital, 0274\u20131 and 0274\u20133; Nagaoka Chuo General Hospital Ethics Committee, 541; The Research Ethics Review Committee of NHO Nagoya Medical Center, 2022\u2013024; The Ethics Review Committee of Toyama City General Hospital, 2022\u201307.","order":3,"name":"Ethics","label":"List of ethics committees and approval numbers","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}